Novo Nordisk

Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…

Weight loss drug maker Novo Nordisk has seen shares slump after warning over a sales plunge amid price…

Jan 30 (Reuters) – Novo Nordisk’s Wegovy pill hits over 26,000 U.S. prescriptions in ‌the second full week…

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s new once-daily pill for weight management, designed…

This article first appeared on GuruFocus. Roche Holding AG (RHHBY) is beginning to show tangible progress in obesity…

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…

Cash-pay platform brings transparent pricing and direct provider access to first and only oral GLP-1 weight loss medication…

Novo Nordisk had a rough stretch in 2025 that eventually led to it “firing” its CEO. The new…

Novo Nordisk’s Ozempic kicked off the GLP-1 craze when it launched in 2018 for the treatment of Type…

Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified…

Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…

Health Canada has approved a GLP-1 pill for the first time. The once-a-day semaglutide pill is approved for…

Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026